摘要【目的】比较吉非替尼联合放化疗与单纯放化疗治疗肺癌脑转移的疗效及安全性。【方法】本院收治的肺癌脑转移患者106例,随机分为两组,每组53例,对照组给予单纯放化疗治疗,观察组在放化疗的基础上给予吉非替尼治疗,比较两组近远期疗效、生活质量及毒副反应发生率。【结果】观察组与对照组比较,脑转移病灶治疗有效率(60.38% vs 37.74%)、全身治疗有效率(62.26% vs 35.85%)、生活质量提高率(73.58% vs 39.62%)、无进展生存期[(7.26±1.82) vs (4.51±2.03)个月]、总生存期[(13.14±2.27) vs (8.42±2.15)个月]、骨髓抑制发生率(7.55% vs 35.85%)观察组均优于对照组,且差异有显著性(P＜0.05);两组血液毒性反应、消化道反应、肝功能损伤等毒副反应的发生率比较差异无显著性(P＞0.05)。【结论】吉非替尼联合放化疗治疗肺癌脑转移可提高临床治疗效果、延长生存期、提高生活质量、降低骨髓抑制的发生率。
[1]D'Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies[J]. Ther Adv Med Oncol. 2014,6(3):101-114. [2]Yamagishi T, Fujimoto N, Miyamoto Y, et al. Brain metastases in malignant pleural mesothelioma[J]. Clin Exp Metastasis. 2016,33(3):231-237. [3]苏加利,冯字清,朱道奇，等.全脑放疗联合吉非替尼治疗EGFR突变阳性肺腺癌脑转移[J].医学临床研究,2015,32(9):1764-1766. [4]中国医师协会肿瘤医师分会,中国抗癌协会肿瘤临床化疗专业委员会.中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2013版)[J].中华肿瘤杂志,2013,35(6):478-480. [5]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C].//第三届中国肿瘤内科大会论文集.2009:123-125. [6]Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer[J]. J Clin Oncol. 2013,31(7):895-902. [7]Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J]. Lung Cancer. 2013,82(2):282-287. [8]Halasz LM, Uno H, Hughes M, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer[J]. Cancer. 2016 ,122(13):2091-2100.
2017, Vol. 34 
